Drug record
What four public record sets show for hydrochlorothiazide. Saved Nov 10, 2026.
| Shortage | On the FDA shortage list | Details |
|---|---|---|
| Pharmacy cost | $0.011 each for the lowest-cost generic | Details |
| Medicare Part D, 2024 | $81.2 million | Details |
| FDA recall records | 128 | Details |
Whether the FDA lists this drug as in short supply.
Reason given: Discontinuation of the manufacture of the drug
Reason given: Discontinuation of the manufacture of the drug
Reason given: Discontinuation of the manufacture of the drug
2 products being discontinued. A maker has told the FDA it will stop making these. That is one maker leaving, not a shortage of the drug:
The list changes daily, and it covers the national supply. A pharmacy near you can be out of a drug that is not listed, or have one that is. See today's status.
The national average price retail pharmacies pay to buy it (NADAC).
The lowest-cost generic on file is Hydrochlorothiazide 25 Mg Tab: pharmacies pay about $0.011 each, or $0.343 for 30.
| Product as surveyed | Type | Pharmacy pays | For 30 | Price since |
|---|---|---|---|---|
| HYDROCHLOROTHIAZIDE 12.5 MG CP | Generic | $0.027 per each | $0.818 | Oct 21, 2026 |
| HYDROCHLOROTHIAZIDE 12.5 MG TB | Generic | $0.036 per each | $1.08 | Oct 21, 2026 |
| HYDROCHLOROTHIAZIDE 25 MG TAB | Generic | $0.011 per each | $0.343 | Oct 21, 2026 |
| HYDROCHLOROTHIAZIDE 50 MG TAB | Generic | $0.031 per each | $0.935 | Oct 21, 2026 |
This is not your price. NADAC is the national average that retail pharmacies pay to buy the drug, from the Medicaid survey for the week of Nov 11, 2026. What you pay adds the pharmacy's markup and dispensing fee and depends on your insurance or any discount card. "For 30" is shown only for products priced per tablet or capsule. Brand prices here are before any rebates.
Medicare Part D spending by product, from the latest annual file (2024).
In 2024, Medicare Part D plans and their members paid $81.2 million for the 1 product below. That is down 27% from $110.7 million in 2020.
| Product | 2024 spending | People | Per prescription | Per person, year | 2020 spending |
|---|---|---|---|---|---|
| Hydrochlorothiazide Hydrochlorothiazide | $81.2 million | 4,944,477 | $4.40 | $16.42 | $110.7 million |
Spending is the gross amount paid at the pharmacy by Part D plans and patients, before manufacturer rebates, which can be large for brand drugs. The same person can use more than one product, so people are not added up across rows. A dash means the file suppresses a small number or has no figure for that year. Not counted here, combination products that contain it: Amiloride-Hydrochlorothiazide, Avalide, Benazepril-Hydrochlorothiazide, Benicar HCT, Bisoprolol-Hydrochlorothiazide, Captopril-Hydrochlorothiazide, Diovan HCT, Enalapril-Hydrochlorothiazide, Fosinopril-Hydrochlorothiazide, Hyzaar, Irbesartan-Hydrochlorothiazide, Lisinopril-Hydrochlorothiazide, Losartan-Hydrochlorothiazide, Lotensin HCT, Metoprolol-Hydrochlorothiazide, Olmesartan-Hydrochlorothiazide, Quinapril-Hydrochlorothiazide, Valsartan-Hydrochlorothiazide, Vaseretic, Zestoretic.
Recalls reported to the FDA that name this drug.
The FDA has 128 recall records that name hydrochlorothiazide in the product description (1 Class I · 113 Class II · 14 Class III). 47 are still marked ongoing.
Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets 40 mg/10 mg/12.5mg, packaged as a) 30-count bottle, NDC 33342-246-07; b) 90-count bottle, NDC 33342-246-10; Rx Only, Manufactured for : Macleods Pharma USA, Inc. Princeton, NJ 08540, Manufactured by: Macleods Pharmaceuticals Ltd, Daman, 396210, India
Reason: Failed Dissolution Specifications.
Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg, 100-count bottle, Rx Only, Manufactured by: UNICHEM LABORATORIS LTD., Pilerne Ind. Estate, Pilerne, Bardez, Goa 403 511, India, Manufactured for: UNICHEM PHARMACEUTICALS (USA), INC., East Brunswick, NJ 08816, NDC 29300-187-01
Reason: cGMP Deviations: recall due to not meeting the N-Nitroso Bisoprolol impurity specification limits.
Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 2.5 mg/6.25 mg, packaged as (a) 30-count bottles, NDC-68462-878-30; (b) 100-count bottle, NDC-68462-878-01; (c) 500-count bottles, NDC-68462-878-05; Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, Inda. Manufactured for: Glenmark Pharmaceuticals, Inc., USA, Mahwah, NJ 07430.
Reason: Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe
Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, 100-count bottles, Rx only, Mfg for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202, Manufactured by: Lupin Limited Nagpur-441 108, INDIA, NDC 68180-519-01
Reason: Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.
Losartan Potassium and Hydrochlorothiazide Tablets, USP 50mg /12.5 mg, 1000-count bottle, Rx only, Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540, Manufactured by: Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh, INDIA, NDC 33342-050-44
Reason: Presence of foreign substance: plastic-like substance.
Triamterene and Hydrochlorothiazide Capsules, USP, 37.5 mg/25 mg, 100 capsules per bottle, Rx Only, Distributed by: Lannett Company, Inc, Philadelphia, PA 19136. NDC 0527-1632-01
Reason: CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Lisinopril and Hydrochlorothiazide Tablets USP, 10mg/12.5mg, Rx only, 100 Tablets per bottles, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Nagpur-441 108, India. NDC: 68180-518-01
Reason: CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 5mg/6.25mg, 100-count Bottle, RX only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC 68462-879-01
Reason: Failed Impurities/Degradation Specifications
Triamterene and Hydrochlorothiazide Capsules, USP (37.5 mg/25 mg), Rx Only, [100 or 1000 ] Capsules per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC 100 Count bottle: 0527-1632-01; NDC 1,000 bottle: 0527-1632-10
Reason: Failed Impurity/Degradation Specifications
Triamterene and Hydrochlorothiazide Capsules, USP (37.5 mg/25 mg), Rx Only, 1000 Capsules per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC: 0527-1632-10
Reason: Failed Impurity/Degradation Specifications
Quinapril and Hydrochlorothiazide Tablets, USP 20mg/12.5mg, 90 Tablets bottles Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520, Made in India, NDC 65862-162-90
Reason: CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.
Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/25 mg, 30 Tablets, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot no 2, Phase-2, Pharma Zone, SEZ Pithampur, District Dhar, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc, USA, Mahwah, NJ 07430, NDC 68462-842-13.
Reason: Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .
A recall covers specific lots from one company, not every bottle of the drug. Records include combination products and compounded versions that name this ingredient. Class I is the most serious: use could cause serious harm. Class II may cause temporary or reversible harm. Class III is unlikely to cause harm. To check a bottle, match the lot number on the label. See the live list. Do not stop a medicine because of a recall without asking your pharmacist.
These are saved records as of Nov 10, 2026; the sources update daily to yearly. For current figures open the live report for hydrochlorothiazide. This page is public-record information, not medical advice.